BRCA1 and ovarian serous adenocarcinoma: Given the clinical benefits demonstrated in this study, both the FDA and EMA approved rucaparib for the maintenance treatment of high-grade serous ovarian cancer (HGOC), regardless of BRCA1/2 status.